Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. announced several corporate updates, including leadership changes and a cost‑reduction initiative. Former President and CEO Keith J. Sullivan entered an Executive Consulting and Release Agreement and will provide consulting services through March 31, 2027 while continuing to vest in his existing equity awards.
The company initiated a workforce reduction affecting up to 5% of employees, expecting about $0.2 million in second‑quarter 2026 restructuring charges and annualized cost savings of roughly $2.5 million to $3.0 million, with most savings beginning in the third quarter of 2026. Executive Vice President, Chief Financial Officer, and Treasurer Steven E. Pfanstiel plans to resign effective May 1, 2026, and a search for his successor is underway.
Neuronetics also issued a press release reaffirming the financial guidance it provided during its fourth quarter 2025 earnings call, indicating that its revenue and expense expectations for fiscal 2026 remain unchanged despite these organizational changes.
Neuronetics, Inc. announced several corporate updates, including leadership changes and a cost‑reduction initiative. Former President and CEO Keith J. Sullivan entered an Executive Consulting and Release Agreement and will provide consulting services through March 31, 2027 while continuing to vest in his existing equity awards.
The company initiated a workforce reduction affecting up to 5% of employees, expecting about $0.2 million in second‑quarter 2026 restructuring charges and annualized cost savings of roughly $2.5 million to $3.0 million, with most savings beginning in the third quarter of 2026. Executive Vice President, Chief Financial Officer, and Treasurer Steven E. Pfanstiel plans to resign effective May 1, 2026, and a search for his successor is underway.
Neuronetics also issued a press release reaffirming the financial guidance it provided during its fourth quarter 2025 earnings call, indicating that its revenue and expense expectations for fiscal 2026 remain unchanged despite these organizational changes.
Madryn-affiliated funds reallocated Neuronetics, Inc. common stock between related vehicles. Two bona fide gift transfers on July 10, 2025 moved a total of 674,624 shares of common stock for no consideration between Madryn Health Partners II, LP and Madryn Health Partners II (Cayman Master), LP for fund administration purposes.
Following the transfers, one fund held 1,430,953 shares of Neuronetics common stock and the other held 17,044,940 shares. Madryn Asset Management, LP serves as investment advisor to both funds, and related Madryn entities may be deemed beneficial owners, while each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Jorey Chernett filed a Schedule 13D reporting a large stake in Neuronetics, Inc. He beneficially owns 9,778,718 shares of common stock, representing about 14.12% of the 69,276,593 shares outstanding as of March 10, 2026.
The shares were acquired in private transactions using personal funds totaling $19,557,436. Chernett holds sole voting and dispositive power over all reported shares and describes himself as a private investor who believed the stock was undervalued when purchased. He currently has no specific plans for corporate actions but may buy or sell more shares and may engage with management, the board, and other stockholders about strategy, capital structure, governance, or potential business combinations.
Neuronetics, Inc. ten percent owner Jorey Chernett reported an open-market purchase of 385,442 shares of common stock at a weighted average price of $1.25 per share. After this transaction, Chernett directly beneficially owned 9,778,988 shares of Neuronetics common stock.
The shares were acquired in multiple trades at prices ranging from $1.23 to $1.26 per share, calculated on a weighted average basis. The filing also corrects a prior clerical error, noting that the previously reported beneficial ownership had been understated by 270 shares.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 500,000 shares of Common Stock at a weighted average price of $1.35 per share. The shares were bought in multiple trades between $1.28 and $1.41. Following this transaction, Chernett directly holds 9,393,276 shares.
Neuronetics, Inc. 10% owner Jorey Chernett reported open-market purchases of a total of 150,000 shares of common stock. The buys occurred on March 25 and March 26 at reported prices of $1.40 and $1.44 per share, respectively. After these transactions, Chernett directly owns 8,893,276 Neuronetics shares. A footnote explains that one purchase reflects a weighted-average price for multiple trades executed between $1.38 and $1.42 per share.
Neuronetics EVP, CFO and Treasurer Steven Pfanstiel reported an open-market sale of 16,431 shares of common stock at a weighted average price of $1.34 per share. According to the footnotes, these were non-discretionary sales made solely to satisfy tax withholding obligations upon vesting of a performance restricted stock unit award. After the transaction, Pfanstiel directly holds 828,781 shares of Neuronetics common stock, indicating this was a relatively small, tax-driven adjustment to his overall position rather than a discretionary portfolio move.
Former officer and director Keith J. Sullivan of Neuronetics, Inc. reported an open-market coded sale of 46,289 shares of common stock at a weighted average price of $1.34 per share. According to the footnotes, these were non-discretionary sales made solely to satisfy his tax withholding obligation upon vesting of a performance restricted stock unit award.
The shares were sold in multiple trades at prices ranging from $1.48 to $1.20 per share. After these transactions, Sullivan directly holds 1,590,924 shares of Neuronetics common stock, indicating he retained a substantial equity position following the tax-related disposition.
Neuronetics, Inc. executive William Andrew Macan reported an open-market sale of 16,005 shares of common stock at a weighted average price of $1.34 per share. According to the disclosure, these were non-discretionary sales made solely to cover tax withholding upon vesting of a performance restricted stock unit award, and he continues to hold 897,270 shares directly.
REUVERS DANIEL L. reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. President and CEO Daniel L. Reuvers reported an equity compensation award of 1,500,000 shares of common stock on March 23, 2026, coded as a grant. The award is structured as restricted stock units that vest in three equal annual installments beginning on March 23, 2027, subject to his continuous service. Each RSU gives a contingent right to receive one share of common stock, and following this award he reports 1,500,000 shares/units held directly.